NanoVibronix today received publication of guidance from National Institute for Health and Care Excellence (NICE) in the U.K. for its UroShield device.
England’s Department of Health and Social Care’s NICE issued guidance suggesting that UroShield has the potential to provide significant patient and healthcare system benefits to prevent catheter-associated urinary tract infections. Further U.K.-based research was recommended to confirm the positive results shown for people with long-term catheters and to determine whether people with short-term catheters would benefit from UroShield.
U.K.’s NICE reported that a cost analysis of UroShield suggested the device could be cost-saving in hospitals and for people with repeated UTIs or catheter blockages in community care. The agency also recommended the expansion of use by England’s National Health Service patients to further real-world evidence data collection.
UroShield is an ultrasound-based system that is designed to prevent bacterial colonization and biofilm on indwelling urinary catheters while also increasing antibiotic efficacy to reduce the incidence of catheter-associated urinary tract infections.
